Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, ADX-102, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.
Due to Aldeyra’s strong intellectual property position, our research has identified numerous potential targets including inflammatory diseases and diseases known an inborn errors of metabolism that result from genetic mutations in aldehyde-metabolizing proteins. Accordingly, we have developed a series of promising product candidates designed specifically to trap and mitigate the toxic effects of aldehydes.
We are a publicly traded company on the NASDAQ exchange, ticker ALDX.